EL7.AI
Mergers & AcquisitionsMediumUpdated×2•Originally published 16 November 2026•Updated 16 November 2026•
5 min read

Merck to Acquire Rapid Micro at $0.75 per Share in Cash

Key Facts

1Merck agreed to buy all of Rapid’s outstanding shares for $0.75 per share in cash.
2Rapid’s third-quarter 2026 revenue was $9.5 million, up 21.6% from the corresponding period.
3Total gross margin reached a quarterly record of 25%, up 16 percentage points year over year.
4The deal is expected to close in December 2026, after the tender-offer and closing conditions are met.
5The company withdrew its 2026 guidance and delayed filing its quarterly report.

On November 16, 2026, Rapid Micro Biosystems announced it had signed a definitive agreement under which Merck, headquartered in Darmstadt, Germany, would acquire all of its outstanding shares for $0.75 per share in cash. The agreement remains subject to its terms and conditions, and the tender offer had not begun when it was announced. In its quarterly results statement, Rapid reported third-quarter revenue of $9.5 million, up 21.6% from $7.8 million in the corresponding period of 2025. The announcement puts the deal and the company’s latest results at the center of the development, while the disclosure did not include a total purchase price. Following completion of the deal, Rapid is expected to become part of Merck’s Life Science business.

Third-quarter results came with improved gross margins, as the company reported a total gross margin of 25%, which it described as a quarterly record. The total margin increased 16 percentage points year over year. Product margin rose 19 percentage points to 12%, while service margin climbed 14 percentage points to 54%. These figures show the different margin levels across the company’s product and service businesses. They also accompanied an increase in total revenue, which reached $9.5 million in the quarter.

By revenue component, product revenue rose 24.9% to $6.5 million in the third quarter, while service revenue increased 14.9% to $3.0 million. Recurring revenue was $5.2 million, up 6.9% from the corresponding period a year earlier. The company also reported figures for Growth Direct system activity, placing 7 new systems during the quarter. It also completed validation of 12 systems at customer sites. In the third quarter of 2025, it had placed 5 systems and completed validation of 4, according to the company’s comparison.

Chief Executive Robert Spignesi said the two companies had built a partnership over the previous 18 months, and that Rapid’s joining Merck’s Life Science business could broaden the reach of Growth Direct and accelerate its adoption. The platform automates microbial quality-control testing used in drug manufacturing, according to the company. Paolo Carli of Merck said customers need “reliable results faster, more efficient quality-control workflows, and strong data integrity to support regulatory compliance.” He added that Rapid would strengthen automation in drug manufacturing. The two companies had begun a commercial collaboration before the acquisition agreement.

In February 2025, Rapid and Merck entered into a five-year global distribution and collaboration agreement through Merck’s Life Science unit, which operates in the United States as MilliporeSigma. The agreement granted MilliporeSigma joint global rights to sell Growth Direct systems and related consumables. Rapid retained responsibility for installing, validating and servicing the systems. MilliporeSigma also committed to purchasing a minimum number of systems in each of the agreement’s first two years. In the second quarter of 2026, Rapid said it had reached 200 Growth Direct systems placed globally, with 4 systems placed and 9 customer systems validated during that quarter.

Rapid’s second-quarter 2026 revenue was about $8.1 million, up 10.9% from $7.3 million a year earlier, according to its disclosure. In the latest cash balance reported in its results, cash and cash equivalents and short-term investments totaled about $7 million as of September 30, 2026. The company did not provide figures on the market’s response to the deal on the day it was announced. The stock’s close at $0.651 and Merck’s close at $33.07 were on November 13, three days before the announcement, and do not represent trading afterward. These two values therefore do not reflect movements in either stock following the deal announcement.

After announcing the deal, Rapid withdrew its 2026 financial guidance and said it would not hold a conference call to discuss third-quarter results. It also announced that it would delay filing its quarterly “10-Q” report while it worked through reporting and disclosure matters related to the acquisition. It said it intended to file the report within the extension period permitted under Rule 12b-25. Regarding the deal, Merck and EMD Holding Newco 2 were required to file a “Schedule TO,” and Rapid was required to file a “Schedule 14D-9” when the offer commenced. The company had cited risks including failure to obtain the necessary regulatory approvals or receive tenders for a sufficient number of shares, as well as litigation and the possibility of delay or failure of the deal and impacts on business relationships.

The deal is expected to close in December 2026, subject to completion of the tender offer and satisfaction of the minimum tender condition, as well as customary closing conditions. Signing the agreement does not mean the offer has begun, as the regulatory disclosures noted above were still required. The company also tied the transfer of Growth Direct to Merck to completion of the transaction. Rapid appointed Perella Weinberg Partners as financial adviser and Goodwin Procter as legal adviser. Completion of the acquisition remains subject to the steps and approvals set out in the agreement.

Open on chart